Aspen Pharmacare Holdings Limited Overview
FY2023 is from the sustainability supplement. FY2025 is from the Profile's Handbook (2025 Issue 2). FY2024 and post-divestment FY2026 headcounts were not captured. Third-party data aggregators show 8,867 and 9,557, and these are not reconcilable.
Aspen Pharmacare is Africa's largest pharmaceutical company. It is a JSE-listed specialty and branded multinational, run by its co-founder and Group CEO Stephen Saad. It operates through two segments. Commercial Pharmaceuticals (about 73% of FY2026 continuing revenue) markets post-patent branded prescription, OTC and hospital injectable medicines in emerging and developed markets. Manufacturing (about 27%) runs sterile finished-dose (FDF), oral and API plants in South Africa, France and the Netherlands, among other sites, and serves both internal and third-party contracts. FY2026 was a reset year. The R28bn sale of APAC to BGH Capital moved the group from about R31bn of net debt to net cash. Restructuring of the sterile plants in France and South Africa repaired Manufacturing profitability after an mRNA contract was lost. Mounjaro in South Africa became the main growth driver in Commercial Pharma. The investment case now depends on GLP-1s (in-licensed tirzepatide marketing and its own generic semaglutide), sterile capacity fill (insulin, vaccines, GLP-1) and capital returns.
Company's own description
Aspen describes itself as a global specialty and branded pharmaceutical company. It says it improves patient health through high-quality, affordable medicines, is active at every stage of the value chain, and is diversified by geography, product and manufacturing capability (aspenpharma.com investor hub). Its stated strategy has three parts: build product portfolios that achieve organic growth, build a differentiated portfolio of relevant IP, and use complex manufacturing capability plus a globally integrated supply chain to create value and enable access to medicines (investor hub, 2026). Its purpose statement is to improve the health and quality of life of patients. The corporate credo is "Healthcare. We Care."
Independent characterisation
In practice Aspen has three economic engines.
-
A brand-acquisition and in-licensing commercial platform (Commercial Pharmaceuticals). Since 1997 Aspen has bought mature, off-patent or non-core brands from multinationals, including GSK, AstraZeneca, MSD, Viatris and Sandoz. It markets them through its own affiliates, mainly in emerging markets: Sub-Saharan Africa, the Middle East, Latin America and China. It increasingly also distributes innovator products in South Africa and Sub-Saharan Africa under long-term agreements with Eli Lilly and Boehringer Ingelheim. Revenue is product sales, priced under regulated systems such as South Africa's Single Exit Price and China's volume-based procurement (VBP). There is no material subscription or licensing-fee income.
-
A multi-site manufacturing business (Manufacturing). This makes FDF products (sterile injectables, oral solids, liquids, semi-solids) and APIs, including hormones and specialised chemistry at Oss (Netherlands) and Fine Chemicals Corporation (Cape Town), plus heparin, now on a working-capital-light toll model. Revenue comes from contract manufacturing (CMO/CDMO) for third parties, internal supply and API sales. This segment carries Aspen's largest fixed-cost and execution risk, which became visible when the mRNA contract was lost in FY2025.
-
An emerging GLP-1 and specialty access franchise. Aspen distributes Lilly's Mounjaro in South Africa and Sub-Saharan Africa and holds licensed IP for generic semaglutide, approved in Canada in July 2026. It has also secured access licences such as MSD's alimatravir for HIV prevention (July 2026) and Serum Institute paediatric vaccines (2022).
Revenue model mix (FY2025, total operations)
| Revenue type | FY2025 ZAR Mn | Share of group (%) | Basis |
|---|---|---|---|
| Branded product sales – Prescription | 12,519 | 28.9 | FY2025 segmental analysis |
| Branded product sales – OTC | 9,812 | 22.6 | FY2025 segmental analysis |
| Branded product sales – Injectables | 9,885 | 22.8 | FY2025 segmental analysis |
| Manufacturing – FDF (third-party and contract) | 5,099 | 11.8 | FY2025 revenue analysis |
| Manufacturing – API | 4,718 | 10.9 | FY2025 revenue analysis |
| Manufacturing – Heparin | 1,330 | 3.1 | FY2025 revenue analysis |
| Total | 43,363 | 100.0 | — |
Subscription and licensing-fee revenue is not separately disclosed and appears immaterial.
Value-chain position, customers and end-markets
Value chain: Aspen covers API synthesis, FDF manufacture (sterile and non-sterile), regulatory registration, marketing and distribution. Upstream discovery R&D is limited; the group relies on in-licensing and acquired IP.
Customer types: - Public-sector tender buyers, such as South African state ARV and insulin tenders and China's VBP.
-
Private wholesalers and pharmacies (OTC and prescription).
-
Hospitals (anaesthetics and injectables).
-
Multinational pharma contract customers (FDF and API toll and contract manufacturing).
-
Multilateral buyers for vaccines (the target for the Serum Institute and Africa CDC frameworks).
End-markets: anaesthesia, thrombosis, oncology (legacy cytotoxics), metabolic/diabetes and obesity (Mounjaro, semaglutide, insulin), pain and central nervous system (Lyrica, Celebrex in Latin America), consumer health and OTC, infectious disease (HIV, vaccines) and hormones (API).
Strategy
Stated strategy (paraphrased from FY2025–FY2026 disclosures)
-
Build sustainable organic growth in Commercial Pharmaceuticals, focused on emerging markets and supported by multinational partnerships (Lilly, Boehringer Ingelheim, Viatris, Sandoz).
-
Monetise the GLP-1 opportunity through two routes: in-licensed branded products (Mounjaro) and Aspen's own and licensed generic semaglutide IP. These feed both commercial sales and manufacturing volumes.
-
Restore and fill Manufacturing capacity. This means reshaping loss-making sterile FDF plants, commercialising insulin and vaccines, and winning third-party CDMO and API contracts.
-
Unlock sum-of-the-parts value. APAC was sold at about 11x FY2025 EBITDA. The board says the share price does not fully reflect intrinsic value (SENS, 29 May 2026).
-
Capital discipline: pay dividends at 20% of NHEPS, deleverage, then use share buybacks to increase shareholder returns (FY2026 prospects).
Initiatives in the last 24 months
| Initiative | Date | Description | Target / status | Source |
|---|---|---|---|---|
| China reshape | FY2025–FY2026 | Integration of Sandoz China; discontinue unprofitable products | Restructuring about R0.5bn plus R0.3bn inventory write-offs (FY2025). Margin accretive in FY2026. | FY2025 and FY2026 results |
| Sterile FDF reshape (France and South Africa) | 2025–2026 | Match resources to contracts on hand | R695m restructuring in H1 2026. Sterile FDF delivered R1.2bn of the R1.7bn FY2026–FY2027 uplift guidance in FY2026. Guidance raised to R2.2bn. | FY2026 results |
| Group efficiency and value-enhancement projects | FY2026 | Projects across the group | R2.3bn restructuring cost in FY2026 | FY2026 results |
| GLP-1: generic semaglutide | 2024–2027 | Own and licensed IP; multi-dose pen and autoinjector; production in South Africa and France | Canada approved (Jul 2026). About 20 registrations pending (Brazil, South Africa and others). Global rollout from FY2027. | FY2025 results; Business Day (2 Sep 2026) |
| GLP-1: Mounjaro expansion | 2025–2026 | Rollout across Sub-Saharan Africa | Nigeria and Kenya registrations pending | Business Day (2 Sep 2026) |
| Insulin contract | Commercial from May 2026 | Human insulin technology transfer to Gqeberha | More than R1bn revenue targeted in FY2027 | FY2025 and FY2026 results |
| Vaccines | 2022–2026+ | Serum Institute products; Africa CDC demand framework | SAHPRA/WHO approvals pending. Africa CDC framework in "advanced discussions" (May 2026). | FY2025 results; Aspen release (12 May 2026) |
| HIV prevention access | Jul 2026 | MSD alimatravir licence covering 129 countries | Dependent on Phase III results and regulatory approval | Business Report (24 Jul 2026) |
| APAC divestment | Dec 2025 – May 2026 | Sale to BGH Capital | Completed; net cash achieved | SENS 29 May 2026 |
| Share buybacks | May–Aug 2026 | Open-market repurchases | R0.5bn at an average of about R148.17 per share | Daily Investor (Sep 2026) |
| Sustainability (Mandela Day and others) | Ongoing | Social investment | More than 920,000 beneficiaries reported (2026) | aspenpharma.com news |
Medium-term targets and guidance (FY2027)
| Guidance item | Target | Source |
|---|---|---|
| Group normalised EBITDA (CER) | At least R9bn (versus about R7.7bn in FY2026) | FY2026 results |
| NHEPS growth (CER) | "Substantial double-digit", quantified on the call as more than 50% | FY2026 results; Investing.com transcript |
| Net interest savings | About R1.2bn | FY2026 results |
| Commercial Pharma | Mid-single-digit CER growth in revenue and EBITDA, excluding GLP-1 rollout upside | FY2026 results |
| Manufacturing normalised EBITDA (CER) | More than double FY2026 (i.e. above R1.66bn) | FY2026 results |
| Sterile FDF cumulative EBITDA uplift (FY2026–FY2027) | Raised from R1.7bn to R2.2bn | FY2026 results |
| API | Return to growth on new third-party contracts | FY2026 results |
| Free cash flow | Stronger than FY2026 | Quartr summary |
Products & Services
Aspen does not publish a complete SKU-level catalogue in its condensed results. The list below includes only brands and offerings named in the filings and announcements reviewed. Launch years, specifications and pricing are given only where disclosed.
Commercial Pharmaceuticals — Injectables (hospital and specialty)
| Product / franchise | Description | Target customer | Status / notes | Source |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | Lilly's GIP/GLP-1 agonist for type 2 diabetes and chronic weight management. Aspen promotes and distributes it under licence in South Africa and other Sub-Saharan African markets. | Diabetes and obesity patients; private payers | Launched Dec 2024 (T2D). KwikPen approved 2025. Weight-management indication later approved. Registration pending in Nigeria and Kenya. Saad said on the Sep 2026 call that Mounjaro drove about 40% of group growth. | Business Day (2 Sep 2026; 28 Oct 2025); FY2025 results |
| Diprivan (propofol) | Anaesthetic from the AstraZeneca anaesthetics portfolio | Hospitals | Affected by slower post-VBP recovery in China. Impairment in FY2025. | FY2025 results note L |
| Naropin (ropivacaine) | Local anaesthetic from the AstraZeneca portfolio | Hospitals | EEA rights sold to Sandoz (2024). The post-VBP recovery was better than expected, leading to an impairment reversal in FY2025. | SENS 4 Dec 2023; FY2025 note L |
| Fraxiparine (nadroparin) | Low-molecular-weight heparin from the GSK thrombosis business | Hospitals | China VBP pressure; impaired in FY2025 | FY2025 note L |
| GSK anaesthetics portfolio | Anaesthesia products, including Nimbex and Tracrium outside the EEA | Hospitals | Competition and price pressure; impaired in FY2025 | FY2025 note L |
| Sandostatin (octreotide) | Acromegaly and neuroendocrine tumour therapy, acquired with Sandoz China | Specialist hospitals, China | Part of about R1.8bn of annual sales added | Aspen release (Dec 2023) |
| Aclasta (zoledronic acid) | Bone disease and osteoporosis infusion, acquired with Sandoz China | Hospitals, China | Acquired 2024 | Aspen release (Dec 2023) |
| Voriconazole | Antifungal, acquired with Sandoz China | Hospitals, China | Acquired 2024 | Aspen release (Dec 2023) |
| Aspen-Semaglutide (generic Ozempic) | Generic semaglutide injection for type 2 diabetes, in multi-dose pen and autoinjector formats | Diabetes patients in early patent-expiry markets | Health Canada approval on 20 Jul 2026. Launch depends on API supply from Dr. Reddy's. About 20 further registrations pending, including Brazil and South Africa. Bigger volumes are planned from the South African sterile plant. | FilingReader (20 Jul 2026); Business Day (2 Sep 2026); Medical Dialogues (21 Jul 2026) |
Commercial Pharmaceuticals — Prescription
| Product / franchise | Description | Region | Source |
|---|---|---|---|
| Viatris Latin America portfolio: Lyrica (pregabalin), Celebrex (celecoxib), Viagra (sildenafil), Lipitor (atorvastatin) | Mature global brands acquired for Latin America in 2023 for about US$280m / R5.3bn | Americas | Business Day (4 Apr 2024); H1 2024 SENS |
| Lilly franchise (Sub-Saharan Africa) | Distribution and promotion of Lilly products. It added to Africa Middle East Prescription growth in FY2025. | Africa Middle East | FY2025 results; H1 2024 SENS |
| Boehringer Ingelheim South Africa portfolio | Long-term distribution and promotion agreement, effective 1 Sep 2025 | South Africa | FY2025 results |
| Specialist global brands | Niche specialty products; three products impaired in FY2025 | Global | FY2025 note L |
| Legacy cytotoxics: Alkeran, Leukeran, Lanvis, Myleran, Purinethol | Off-patent haematological oncology drugs, subject to binding EC price commitments until about 2031 | Europe and global | VBB (Feb 2021) |
| MSD business | Portfolio acquired from MSD; one product impaired in FY2025 | Global | FY2025 note L |
| ARVs and public-sector chronic medicines | Generic antiretrovirals supplied through South African state tenders. Brand-level detail was not captured. | South Africa | TimesLive (Jul 2026) |
| Alimatravir (MK-8527), licensed | Investigational once-monthly oral HIV-1 prevention pill (Phase III) under an MSD voluntary licence covering 129 countries, including all of Africa | Africa and low/middle-income countries | Business Report (24 Jul 2026) |
Commercial Pharmaceuticals — OTC (consumer health)
| Item | Detail | Source |
|---|---|---|
| GSK OTC brands | Legacy consumer brands bought from GSK. Impairment reversal of R153m in FY2025 because the outlook improved. | FY2025 note L |
| GSK classic brands | Mature consumer and Rx brands. Four products impaired in FY2025 because of competition. | FY2025 note L |
| ELIZ products | Product group with an impairment reversal of R88m in FY2025 | FY2025 note L |
| Africa Middle East OTC | R3,746m revenue in FY2025 (+5%) | FY2025 results |
| Australasia OTC | R2,448m revenue in FY2025 (+5% CER). Divested with APAC on 29 May 2026. | FY2025 results |
Brand-by-brand OTC names for South Africa were not captured in the documents reviewed.
Manufacturing offerings
| Offering | Description | Sites | Status / notes | Source |
|---|---|---|---|---|
| Sterile FDF contract manufacturing | Vials, ampoules, pre-filled syringes and pens; aseptic fill-finish | Gqeberha (South Africa); Notre-Dame-de-Bondeville (NDB, France) | Reshaped in FY2026 (R2.3bn restructuring across the group). Sterile FDF EBITDA uplift guidance raised to R2.2bn cumulative over FY2026–FY2027. | FY2026 results |
| Human insulin contract | Contract manufacture of human insulin after technology transfer | Gqeberha sterile plant | SAHPRA approval received. Commercialisation began in May 2026. Revenue guidance was R0.3bn for FY2026, rising to more than R1bn in FY2027. | FY2025 and FY2026 results |
| Serum Institute vaccines | Pneumococcal, rotavirus, polyvalent meningococcal and hexavalent vaccines, made from Serum bulk drug substance | Gqeberha | Ten-year deal (2022). Regulatory approvals from SAHPRA and WHO are pending. Sales are possible from calendar 2026. | SENS 31 Aug 2022; FY2025 results |
| GLP-1 sterile production | Semaglutide pens and autoinjectors for its own commercial use | Gqeberha and NDB | Onboarding volumes following the semaglutide launches | FY2025 results; Medical Dialogues |
| API (Aspen API / Oss) | Hormones and specialised APIs; CDMO services | Oss (Netherlands); FCC (Cape Town) | FY2025 API revenue R4,718m (-8%). Expected to return to growth in FY2027 on new third-party contracts. | FY2025 and FY2026 results |
| Heparin | Heparin API under a working-capital-light toll model | Europe CIS | FY2025 revenue R1,330m (-65%) | FY2025 results |
| mRNA fill-finish (terminated) | Manufacturing and technology agreement for mRNA products | Sterile FDF | About R1.5bn contribution in H1 2025, then disputed. €25m settlement in Oct 2025. mRNA assets impaired by R753m. | FY2025 results; H1 2026 results |
Pricing model. Commercial products are priced under national regulatory regimes: South Africa's single exit price, China's VBP tenders and European reimbursement systems. Manufacturing is priced per contract (unit price, toll fees, take-or-pay where negotiated). No pricing schedules are publicly disclosed.
Financial Narrative
Income statement and per-share data
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Sub-segments / contents | Notes |
|---|---|---|
Commercial Pharmaceuticals | Prescription; OTC; Injectables. Reported by customer geography: Africa Middle East, Americas, Asia, Europe CIS, and Australasia until FY2025. | Australasia and Asia ex-China (APAC) moved to discontinued operations in H1 2026 |
Manufacturing | Finished Dose Form (sterile and non-sterile); Active Pharmaceutical Ingredients; Heparin. Reported by geography of manufacture. | FDF Australasia (Dandenong) was divested with APAC |
Other | One-off compensation or insurance income not allocated to segments (R549m in FY2024; nil in FY2025) | FY2025 enhanced segmental disclosure |
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Prescription (ZAR Mn) | — | — | 11,380 | 12,519 | — |
OTC (ZAR Mn) | — | — | 9,706 | 9,812 | — |
Injectables (ZAR Mn) | — | — | 9,484 | 9,885 | — |
Commercial Pharmaceuticals total (ZAR Mn) | 27,700 | 30,121 | 30,570 | 32,216 | 25,405 |
Manufacturing (ZAR Mn) | 10,948 | 10,588 | 14,136 | 11,147 | 9,465 |
Group revenue (ZAR Mn) | 38,606 | 40,709 | 44,706 | 43,363 | 34,870 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Commercial Pharmaceuticals normalised EBITDA (ZAR Mn) | 8,859 | 8,923 | — |
Manufacturing normalised EBITDA (ZAR Mn) | 1,847 | 668 | 828 |
Other (ZAR Mn) | 549 | 0 | — |
Commercial Pharmaceuticals EBITDA margin (%) | 29.0 | 27.7 | — |
Manufacturing EBITDA margin (%) | 13.1 | 6.0 | 8.7 |
Commercial Pharmaceuticals gross margin (%) | 59.4 | 58.1 | — |
Manufacturing gross margin (%) | 9.2 | 3.7 | — |
Prescription gross margin (%) | 60.9 | 61.8 | — |
OTC gross margin (%) | 58.7 | 58.3 | — |
Injectables gross margin (%) | 58.2 | 53.2 | — |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Commercial Pharma revenue growth, reported (%) | — | 5 | — |
Commercial Pharma revenue growth, CER (%) | — | 10 | 5 |
Manufacturing revenue growth, reported (%) | — | -21 | -10 |
Commercial Pharma EBITDA growth, CER (%) | — | 10 | 13 |
Manufacturing EBITDA growth, CER (%) | — | -62 | 21 |
Commercial Pharma share of group revenue (%) | 68.4 | 74.3 | 72.9 |
Manufacturing share of group revenue (%) | 31.6 | 25.7 | 27.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (ZAR Mn) | 38,606 | 40,709 | 44,706 | 43,363 | 34,870 |
Gross profit (ZAR Mn) | — | — | 19,454 | 19,129 | — |
Gross margin (%) | — | — | 43.5 | 44.1 | 43.0 |
Operating profit (ZAR Mn) | — | — | 6,998 | 1,437 | — |
Operating margin (%) | — | — | 15.7 | 3.3 | — |
Normalised EBITDA (ZAR Mn) | 11,012 | 11,100 | 11,255 | 9,591 | 7,700 |
Normalised EBITDA margin (%) | 28.5 | 27.3 | 25.2 | 22.1 | 22.1 |
Profit/(loss) before tax (ZAR Mn) | — | — | 5,714 | -123 | — |
Tax (ZAR Mn) | — | — | 1,310 | 960 | — |
Net profit/(loss) for the year (ZAR Mn) | — | — | 4,404 | -1,083 | — |
Net margin (%) | — | — | 9.9 | -2.5 | — |
Basic and diluted EPS (ZAR cents) | 1,432.3 | 1,176.9 | 991.4 | -243.9 | — |
HEPS (ZAR cents) | 1,461.2 | 1,405.4 | 1,356.6 | 792.1 | — |
NHEPS, total operations (ZAR cents) | 1,627.6 | 1,498.5 | 1,492.1 | 1,055.8 | — |
NHEPS, continuing operations (ZAR cents) | — | — | — | 659.2 | 801.5 |
Dividend per share (ZAR cents) | 326 | 342 | 359 | 211 | 232 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | — | — | 139,063 | 135,893 | — |
Cash and cash equivalents (ZAR Mn) | — | — | 12,337 | 6,409 | — |
Borrowings – current (ZAR Mn) | — | — | 11,314 | 4,612 | — |
Borrowings – non-current (ZAR Mn) | — | — | 25,141 | 31,508 | — |
Total borrowings (ZAR Mn) | — | — | 36,455 | 36,120 | — |
Borrowings less cash, computed (ZAR Mn) | — | — | 24,118 | 29,711 | — |
Net debt, company-reported (ZAR Mn) | 16,100 | 22,200 | — | 31,200 | -800 |
Shareholders' equity (ZAR Mn) | — | 86,236 | 84,861 | 84,893 | — |
Goodwill (ZAR Mn) | — | — | 5,696 | 5,202 | — |
Intangible assets (ZAR Mn) | — | — | 66,026 | 67,212 | — |
Goodwill plus intangibles (ZAR Mn) | — | — | 71,722 | 72,414 | — |
Inventories (ZAR Mn) | — | — | 18,002 | 18,009 | — |
Working capital, current assets less current liabilities (ZAR Mn) | — | — | 19,784 | 21,206 | — |
Net debt / EBITDA, company-defined (x) | — | — | — | 3.2 | — |
Cash Flow and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Cash operating profit (ZAR Mn) | — | 9,967 | 10,064 | — |
Cash generated from operations (ZAR Mn) | — | 9,725 | 8,461 | — |
Cash generated from operating activities (ZAR Mn) | — | 6,225 | 5,159 | — |
Operating cash flow per share (ZAR cents) | 1,242.6 | 1,401.4 | 1,161.9 | — |
Cash conversion rate (%) | — | 103 | 147 | — |
Capex – PPE (ZAR Mn) | — | 3,117 | 2,576 | — |
Capex – intangible assets (ZAR Mn) | — | 2,418 | 2,479 | — |
Total capex (ZAR Mn) | — | 5,535 | 5,055 | — |
FCF, operating activities less capex, computed (ZAR Mn) | — | 690 | 104 | — |
Free cash flow before dividends, company-reported (ZAR Mn) | — | — | — | 3,800 |
Dividends paid (ZAR Mn) | — | 1,525 | 1,601 | — |
Share buybacks (ZAR Mn) | — | — | — | 500 |
Treasury shares purchased for incentive schemes (ZAR Mn) | — | 56 | 68 | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE, net profit / year-end equity (%) | 5.2 | -1.3 |
ROA, net profit / year-end total assets (%) | 3.2 | -0.8 |
Current ratio (x) | 1.81 | 2.21 |
Debt / equity, total borrowings / equity (x) | 0.43 | 0.43 |
Net debt / EBITDA, company-reported (x) | — | 3.2 |
Interest cover, normalised EBITDA / interest paid (x) | 5.2 | 5.8 |
Asset turnover, revenue / year-end total assets (x) | 0.32 | 0.32 |
Days inventory outstanding (days) | 260 | 271 |
Days sales outstanding (days) | 103 | 112 |
Days payables outstanding (days) | 150 | 161 |
Cash conversion cycle (days) | 213 | 223 |
Effective tax rate (%) | 22.9 | — |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
Europe CIS revenue (ZAR Mn) | 17,603 | 14,682 |
Africa Middle East revenue (ZAR Mn) | 9,507 | 10,567 |
Americas revenue (ZAR Mn) | 6,711 | 6,843 |
Australasia revenue (ZAR Mn) | 6,685 | 6,311 |
Asia revenue (ZAR Mn) | 4,200 | 4,960 |
Total revenue (ZAR Mn) | 44,706 | 43,363 |
Region growth (%)
| Region growth (%) | FY2025 reported (%) | FY2025 CER (%) |
|---|---|---|
Europe CIS | -17 | -15 |
Africa Middle East | 11 | 13 |
Americas | 2 | 16 |
Australasia | -6 | -1 |
Asia | 18 | 21 |
Total | -3 | 1 |
Revenue by Region — Africa Middle East
| Region | FY2024 | FY2025 |
|---|---|---|
Africa Middle East (ZAR Mn) | 9,021 | 10,086 |
Americas (ZAR Mn) | 6,677 | 6,826 |
Australasia (ZAR Mn) | 5,904 | 5,748 |
Asia (ZAR Mn) | 4,100 | 4,850 |
Europe CIS (ZAR Mn) | 4,868 | 4,706 |
Region Overview
| Region | Prescription | OTC | Injectables | Total CP |
|---|---|---|---|---|
Africa Middle East | 4,569 | 3,746 | 1,771 | 10,086 |
Americas | 3,320 | 1,329 | 2,177 | 6,826 |
Australasia | 2,377 | 2,448 | 923 | 5,748 |
Asia | 1,210 | 316 | 3,324 | 4,850 |
Europe CIS | 1,043 | 1,973 | 1,690 | 4,706 |
Total | 12,519 | 9,812 | 9,885 | 32,216 |
Africa Middle East | 4,242 | 3,561 | 1,218 | 9,021 |
Americas | 2,832 | 1,450 | 2,395 | 6,677 |
Australasia | 2,618 | 2,430 | 856 | 5,904 |
Asia | 697 | 291 | 3,112 | 4,100 |
Europe CIS | 991 | 1,974 | 1,903 | 4,868 |
Total | 11,380 | 9,706 | 9,484 | 30,570 |
Business Lines
| Line | FY2024 | FY2025 |
|---|---|---|
FDF – Europe CIS (ZAR Mn) | 4,131 | 4,159 |
FDF – Australasia (ZAR Mn) | 781 | 563 |
FDF – Africa Middle East (ZAR Mn) | 216 | 250 |
FDF – Asia (ZAR Mn) | 100 | 110 |
FDF – Americas (ZAR Mn) | 34 | 17 |
API – Europe CIS (ZAR Mn) | 4,832 | 4,487 |
API – Africa Middle East (ZAR Mn) | 270 | 231 |
Heparin – Europe CIS (ZAR Mn) | 3,772 | 1,330 |
Revenue by Region (%)
| Currency | FY2024 | FY2025 |
|---|---|---|
Euro share of revenue (%) | 34 | 29 |
South African rand share (%) | 15 | 18 |
Australian dollar share (%) | 14 | 13 |
Chinese yuan share (%) | 5 | 7 |
US dollar share (%) | 6 | 6 |
Mexican peso share (%) | 5 | 4 |
Brazilian real share (%) | 5 | 4 |
British pound share (%) | 2 | 2 |
Canadian dollar share (%) | 2 | 2 |
Colombian peso share (%) | 1 | 2 |
Other currencies share (%) | 11 | 13 |
Share Price History
| Date | Price (ZAR) | Context | Source |
|---|---|---|---|
1 Sep 2022 | About 156 | Technical breakout level cited | TradingView commentary |
Apr 2024 | About 220 (implied) | Market cap R98.2bn | Business Day (4 Apr 2024) |
3 Sep 2024 (open) | About 237 (implied) | Before the FY2024 results sell-off | Daily Investor (Saad stake valuation) |
3 Sep 2024 (close) | About 208 (implied) | After the FY2024 results | Daily Investor |
17 Sep 2025 | About 101 | After the FY2025 loss; 1-year change -47% | Simply Wall St |
30 Apr 2026 | 139.00 | Before APAC completion | Fintel |
29 May 2026 | 144.70 | +7% on APAC completion | Business Report |
Week of 10 Oct 2026 | About 160 | About R69bn market cap; +40% YTD; more than +60% over 12 months | Business Day (10 Oct 2026) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (FY2026 continuing NHEPS 801.5c) | About 20.0x | Derived |
P/E (FY2027 guidance: NHEPS growth above 50%, i.e. above about 1,202c) | Below about 13.3x | Derived from guidance |
EV/EBITDA (FY2026 continuing about R7.7bn) | About 8.9x | Derived; EV about R68bn, excluding leases |
EV/EBITDA (FY2027 target of at least R9bn) | About 7.6x or less | Derived |
EV/Sales (FY2026 continuing R34.9bn) | About 1.95x | Derived |
P/B | About 0.8x (approximate) | FY2026 equity not captured. FY2025 equity was R84.9bn; tangible NAV/share was R156.46 at Jun 2025 (Business Report). |
Dividend yield (232c) | About 1.5% | Derived |
Analyst Ratings & Targets
| Date | Consensus target (ZAR) | Source |
|---|---|---|
Sep 2025 | 120.60 | Simply Wall St |
Apr 2026 | 157.08 average (an earlier revision to 146.20 also noted) | Fintel |
Undated (2026) | 172.67 average across 15 analysts; range 165–183 | Traders Union aggregator |
Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
Dividend per share (ZAR cents) | 0 | 262 | 326 | 342 | 359 | 211 | 232 |
Analyst Conclusions
Management guidance (FY2027)
-
Normalised EBITDA of at least R9bn at CER, versus about R7.7bn in FY2026.
-
NHEPS growth above 50% at CER.
-
Net interest savings of about R1.2bn.
-
Commercial Pharma: mid-single-digit growth in revenue and EBITDA, with GLP-1 rollout as upside.
-
Manufacturing EBITDA more than double FY2026.
-
Sterile FDF uplift guidance raised to R2.2bn cumulative.
-
API returns to growth.
-
Stronger free cash flow.
Sources: FY2026 results; Quartr; Investing.com transcript.
Bull case
-
Operating leverage plus deleveraging compounds per-share earnings. EBITDA of at least R9bn plus about R1.2bn of interest savings supports more than 50% NHEPS growth. On that basis the shares trade at under about 13x FY2027 earnings and about 7.6x EV/EBITDA, with net cash.
-
Two GLP-1 routes to growth. Mounjaro drove about 40% of FY2026 growth. Generic semaglutide adds a second engine across about 20 filings, including Brazil with independent API supply. It also loads the South African and French sterile plants.
-
The Manufacturing earnings base is improving. Insulin (above R1bn in FY2027), the sterile reshape (R1.2bn already delivered) and possible Africa CDC vaccine volumes give visible improvement after two volatile years.
Bear case
-
Manufacturing guidance has a poor track record. COVID vaccine roll-off, the mRNA loss and repeated restructuring (R0.2bn → R0.8bn → R2.3bn) show a history of missed manufacturing targets. A doubling of Manufacturing EBITDA in one year carries high execution risk.
-
Generic semaglutide may be crowded and low-margin. Nine Canadian filers, Dr. Reddy's being first and Aspen's dependence on Dr. Reddy's API could limit Aspen to a small share at falling prices.
-
Reported earnings remain exposed to impairments and currency. R72bn of intangibles and goodwill are sensitive to discount rates, tax rates and China VBP. Rand strength has diluted reported results for two years.
Catalysts and monitorables (next 12 months)
-
Canadian semaglutide launch timing, once Dr. Reddy's API supply resumes (late Oct 2026 or later).
-
Brazil and South Africa semaglutide approvals.
-
Mounjaro approvals in Nigeria and Kenya.
-
H1 FY2027 results (about Mar 2027): delivery of Manufacturing EBITDA and insulin revenue.
-
SAHPRA/WHO approval of the Serum vaccines; any signed Africa CDC framework.
-
Size and pace of buybacks; any further sum-of-the-parts transactions.
-
Chair transition at the Dec 2026 AGM; any CEO succession disclosure.
-
Phase III readout for alimatravir (MSD).
-
Rand trajectory against the EUR, CNY, MXN and BRL.
Analyst verdict
Aspen enters FY2027 in better shape than at any point in the past five years. The APAC sale at about 11x EBITDA turned roughly R31bn of net debt into net cash. It also made the sum-of-the-parts argument concrete. The continuing business held a 22.1% normalised EBITDA margin despite losing its highest-margin region. That outcome reflects real repricing and cost work in China and the sterile plants, and it is more than accounting.
Commercial Pharmaceuticals is still a dependable compounder. It grew EBITDA at double-digit CER rates in both FY2025 and FY2026. Mounjaro has changed the economics of the South African business, and the Lilly, BI and MSD agreements show that multinationals view Aspen as the preferred route into Africa.
The investment case now depends on execution in Manufacturing and GLP-1 generics. History argues for caution in both areas. Aspen has repeatedly lost manufacturing profit to events outside its control or to over-optimistic contract assumptions. The Dr. Reddy's API interruption shows how a third party can delay a launch the company has fully prepared. In generic semaglutide, being first to market matters, and Aspen is not first in Canada.
At about R160, the market already prices in a substantial recovery, at about 20x trailing continuing NHEPS. It does not yet price full delivery of the FY2027 guidance, which implies under about 13x forward. The risk–reward is therefore positive but depends on execution. Each R1bn of shortfall in Manufacturing EBITDA would cut roughly a third of the guided earnings growth (derived).
This research supports a constructive, evidence-contingent view. Three things would validate it:
-
H1 FY2027 Manufacturing EBITDA tracking toward more than R1.6bn;
-
a Canadian or Brazilian semaglutide launch by mid-2027;
-
disciplined use of the net cash position, through buybacks or bolt-ons at sensible multiples.
The view would be undermined by:
-
another large one-off restructuring charge;
-
material new impairments;
-
a slowdown in Mounjaro growth as oral and generic GLP-1s enter South Africa.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / notes | Source |
|---|---|---|---|---|
Stephen Bradley Saad | Group Chief Executive, executive director | Co-founder, 1997 to date | BCom (University of KwaZulu-Natal). Earlier built Zurick Pharmaceuticals, which was sold to Prempharm (Adcock). Chair of The Sharks rugby team. Age 61 per company website (2025). Holds about 12.2–12.8%. | BusinessTech (Feb 2025); aspenpharma.com |
Sean Capazorio | Group Chief Financial Officer, executive director | Not captured | CA(SA). Prepared the FY2025 results. | FY2025 results |
Reginald (RT) Haman | Chief Corporate Officer, executive director | Joined May 2020; CCO from Apr 2021 | Left the board on 1 May 2026; resignation effective 31 Jul 2026 (relocation). Reported pay about R13m a year. | Daily Investor (30 Apr 2026) |
Michael (Gus) Attridge | Co-founder; chief advisor (former Deputy Group CEO) | Since 1997 | Not on the FY2025 director list. Holds about 4.3%. | Daily Investor; Simply Wall St |
Roy Campbell | Investor Relations (joined 2026) | 2,026 | Introduced on the H1 2026 call | Stockalarm transcript |
R Khan | Company Secretary | Not captured | — | FY2025 results |
Board of Directors
| Director | Role | Board since | Background / notes | 2026 status |
|---|---|---|---|---|
Kuseni D. Dlamini | Independent non-executive Chair | 2012 (Chair since 2015) | Former head of Anglo American South Africa | Steps down at the Dec 2026 AGM |
Ben (BJ) Kruger | Independent NED; former Lead Independent Director; former Audit & Risk chair | 2019 | Former co-CEO of Standard Bank Group. Standard Bank NED. University of Pretoria council deputy chair. | Chair-designate from Dec 2026 AGM. Joined Remuneration & Nomination Committee. |
Chris (CN) Mortimer | Non-executive director | 1999 | Legal counsel background; 27-year tenure | Retires Dec 2026 |
Yvonne (YG) Muthien | Independent NED | Not captured | SA Reserve Bank NED; Rhodes Food Group social and ethics chair | Turns 70 in Sep 2026; term extended one year |
Themba (TM) Mkhwanazi | Independent NED | Not captured | Stakeholder and sustainability expertise | Joined Social & Ethics Committee (Jul 2026) |
Linda (L) de Beer | Independent NED | Not captured | Not captured | Continuing |
N Dongwana | Independent NED | Not captured | Not captured | Continuing |
David (DS) Redfern | Independent NED | Not captured | Not captured | Continuing |
Stephen Saad | Executive director (Group CEO) | Founder | — | Continuing |
Sean Capazorio | Executive director (Group CFO) | Not captured | — | Continuing |
Reginald Haman | Executive director | 2020/21 | — | Left 1 May 2026 |
Major Shareholders
| Holder | Stake (%) | Date / source |
|---|---|---|
Government Employees Pension Fund, via the Public Investment Corporation (PIC) | 20.098 | SENS notification, 2 Jul 2026 |
Stephen Saad | 12.2–12.8 | 12.80% at 12 Feb 2025 (Profile's Handbook). He bought a further 853,966 shares for about R101.9m on 7 May 2025 (Simply Wall St). Vendor data varies. |
Coronation Fund Managers | 5.2–8.0 | Simply Wall St (two snapshots differ) |
Sanlam Investment Management | 4.1–4.9 | Simply Wall St |
Michael (Gus) Attridge | 4.3 | Simply Wall St |
BlackRock | 3.8–4.2 | Simply Wall St |
Old Mutual Investment Group | 3.8 | Simply Wall St |
The Vanguard Group | 3.2 | Simply Wall St |
Capital Research & Management | 2.7–4.9 | Simply Wall St |
Schroder Investment Management | 2.7 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlap |
|---|---|---|
South African prescription and OTC | Adcock Ingram (JSE: AIP; NATCO associate) | Largest local listed peer in OTC, prescription and hospital products |
South African and African generics | Cipla (Cipla Medpro South Africa) | Generics, ARVs, public tenders |
Global generics and biosimilars, emerging markets | Sandoz | Generics in China and Europe; also a counterparty |
Global branded generics | Viatris | Mature brands in Latin America and Europe; also a counterparty |
Global generics | Teva | Generics across Europe and emerging markets |
Hospital injectables and anaesthetics | Fresenius Kabi | Propofol and injectable anaesthetics |
Injectables (MENA and Europe) | Hikma | Sterile injectables, MENA branded generics |
Generic GLP-1 (semaglutide) | Dr. Reddy's (also supplier), Sandoz, Teva, Zydus, Alkem and others | Canada and emerging-market semaglutide launches; nine generic filings in Canada |
Branded GLP-1 | Novo Nordisk (Ozempic/Wegovy; oral Wegovy seeking South African approval) | Competes with Aspen-distributed Mounjaro and generic semaglutide |
Sterile CMO/CDMO | Fareva, Delpharm, Recipharm and other European fill-finish CMOs | Third-party sterile contracts for NDB and Gqeberha |
African vaccines | Biovac (South Africa), Institut Pasteur de Dakar and others | Africa CDC vaccine localisation agenda |
Heparin API | Chinese heparin suppliers (e.g. Hepalink) | Heparin pricing and supply |
Peer Comparison FY2025
| Company | Fiscal year | Revenue | Revenue growth | EBITDA / trading margin | R&D intensity | Source |
|---|---|---|---|---|---|---|
Aspen (continuing) | FY Jun 2026 | R34.9bn | Flat (CER) | 22.1% normalised EBITDA | — | FY2026 results |
Aspen (total) | FY Jun 2025 | R43.4bn | -3% reported / +1% CER | 22.1% normalised EBITDA | — | FY2025 results |
Sandoz | FY Dec 2025 | US$11.1bn | Not captured | 21.7% core EBITDA | Not captured | Sandoz FY2025 release (Feb 2026) |
Adcock Ingram | FY Jun 2025 | R9.76bn | +1% | 12.1% trading margin (R1.18bn / R9.76bn, derived) | Not captured | Adcock FY2025 SENS |
Adcock Ingram | FY Jun 2026 | US$592m | Not captured | Not captured | Not captured | Indian Pharma Post (Aug 2026) |
Viatris / Teva / Hikma / Fresenius Kabi | 2025 | — | — | — | — | — |
“—” = not publicly disclosed.



